In the last few years, there has been an increase in research around using psychedelic drugs, like LSD and magic mushrooms, as treatments for mental health conditions. And recently, two Canadian companies working in the sphere have gotten a special designation from a big U.S. regulator that could fast-track the development and review of their drugs.
Sean Silcoff is a journalist with The Globe’s Report on Business. He has been looking at recent developments in these companies and how that fits into the bigger picture of investor excitement around these drugs.
Questions? Comments? Ideas? Email us at thedecibel@globeandmail.com
Can carbon capture solve emissions problems for oil and gas?
Cervical cancer is on the rise in Canada
Why climate change is driving up the cost of your insurance
How a Ukrainian teen fought to get her brother back from Russia
Your personal finance questions answered, with Rob Carrick
What Google’s deal with Canada means for the rest of the world
Ranking Canada’s most livable cities
Tensions over Israel-Hamas war and free speech on campus
Money laundering, crypto trading and Canada’s richest man
Europe’s far-right is moving into the mainstream
The historic rise of rental costs in Canada
How an Ontario city is taking a new approach to homelessness
The Canadian scientist at the centre of the OpenAI drama
Gaza’s underground tunnels
What’s behind the shakeup of Alberta’s health care system
A new twist in the two Michaels saga
The newest nicotine product to spark old fears
After 144 years, bringing home remains from a residential school
The life-or-death limbo of the Afghans who helped Canada
Qatar’s behind-the-scenes role in the Israel-Hamas war
Create your
podcast in
minutes
It is Free
Front Burner
At Issue
The Daily
Today, Explained
Morning Wire